EGFR and lung adenocarcinoma: DUSP6 is upregulated in EGFR- or KRAS-mutant lung adenocarcinoma cells, potentially protecting cells with mutations in the RAS signaling pathway, a proposal supported by experiments with DUSP6-specific siRNAs and pharmacological inhibitors 41.